Company profile: Sensei Bio
1.1 - Company Overview
Company description
- Provider of next-generation cancer immunotherapies from a clinical-stage biotechnology company, including SNS-101, a pH-sensitive monoclonal antibody that selectively targets and inhibits VISTA in the acidic tumor microenvironment to enhance T-cell activation and reduce immune suppression, and the TMAb platform for conditionally active antibodies that activate in low-pH tumors to minimize off-tumor activity.
Products and services
- Clinical-Stage Cancer Immunotherapy Development: Clinical-stage program advancing next-generation immunotherapies, architecting pH-sensitive monoclonal and conditionally active antibodies targeting VISTA in acidic tumor microenvironments to enhance T-cell activation and minimize off-tumor activity
- SNS-101: pH-sensitive monoclonal antibody engineered to selectively target and inhibit VISTA within acidic tumor microenvironments, enhancing T-cell activation and reducing immune suppression
- TMAb Platform: conditionally active antibody engineering platform that selectively activates within low-pH tumor microenvironments to target cancer cells while minimizing off-tumor activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sensei Bio
Iconic Therapeutics
HQ: United States
Website
- Description: Provider of TF-targeting immunoconjugate proteins and monoclonal antibodies for diseases with Tissue Factor overexpression. Offers a licensed anti-TF fusion protein (hI-con1) from Yale; ophthalmology program for retinal diseases (AMD, diabetic retinopathy); inflammation program to modulate cytokines/chemokines; and an oncology program with Exelixis developing an ADC for solid tumors, in Phase I.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iconic Therapeutics company profile →
NewAmsterdam Pharma
HQ: The Netherlands
Website
- Description: Provider of clinical-stage research and development of therapies for cardio-metabolic diseases, including obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor that reduces LDL-C and increases HDL-C for treating metabolic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NewAmsterdam Pharma company profile →
Agalimmune
HQ: United States
Website
- Description: Provider of immunotherapeutic technology, licensing the Alphaject technology from the University of Massachusetts Medical School; located in London, UK and California, USA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agalimmune company profile →
Alzamend Neuro
HQ: United States
Website
- Description: Provider of biotech therapies for Alzheimer's disease that develops and commercializes drugs, treatments, and cures. Includes AL001, an ionic cocrystal delivering lithium via lithium/proline/salicylate for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD; and ALZN002, a cell-based therapeutic vaccine using a mutant-peptide sensitized cell to restore the patient's immune system's ability to combat Alzheimer's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alzamend Neuro company profile →
Active Biotech
HQ: Sweden
Website
- Description: Provider of biotechnology research and development of pharmaceuticals and vaccines, based on knowledge of autoimmune/inflammatory diseases and cancer, developing products to treat conditions including multiple sclerosis and lung and renal diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Active Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sensei Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sensei Bio
2.2 - Growth funds investing in similar companies to Sensei Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sensei Bio
4.2 - Public trading comparable groups for Sensei Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →